Related Experiment Video
Updated: Aug 9, 2026

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract
Published on: June 17, 2014
p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction
S Kesavapany1, K F Lau, D M McLoughlin
1Department of Neuroscience, The Institute of Psychiatry, Denmark Hill, London SE5 8AF, UK.
Abstract:
The neuronal cyclin-dependent kinase p35/cdk5 comprises a catalytic subunit (cdk5) and an activator subunit (p35). To identify novel p35/cdk5 substrates, we utilized the yeast two-hybrid system to screen for human p35 binding partners. From one such screen, we identified beta-catenin as an interacting protein. Confirmation that p35 binds to beta-catenin was obtained by using glutathione S-transferase (GST)-beta-catenin fusion proteins that interacted with both endogenous and transfected p35, and by showing that beta-catenin was present in p35 immunoprecipitates. p35 and beta-catenin also displayed overlapping subcellular distribution patterns in cells including neurons. Finally, we demonstrated that p35/cdk5 phosphorylates beta-catenin. beta-catenin also binds to presenilin-1 and altered beta-catenin/presenilin-1 interactions may be mechanistic in Alzheimer's disease (AD). Abnormal p35/cdk5 activity has also been suggested to contribute to AD. We therefore investigated how modulation of p35/cdk5 activity influenced beta-catenin/presenilin-1 interactions. Inhibition of p35/cdk5 with roscovitine did not alter the steady state levels of either beta-catenin or presenilin-1 but reduced the amount of presenilin-1 bound to beta-catenin. Thus, p35/cdk5 binds and phosphorylates beta-catenin and regulates its binding to presenilin-1. The findings reported here therefore provide a novel molecular framework to connect p35/cdk5 with beta-catenin and presenilin-1 in AD.
Insights
The neuronal p35/cdk5 kinase binds and phosphorylates beta-catenin, regulating its interaction with presenilin-1. This discovery provides a new molecular link between p35/cdk5, beta-catenin, and presenilin-1 in Alzheimer's disease pathogenesis.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- The p35/cyclin-dependent kinase 5 (cdk5) complex is crucial in neuronal function.
- Aberrant p35/cdk5 activity is implicated in Alzheimer's disease (AD).
- Beta-catenin and presenilin-1 interactions are relevant to AD pathology.
Purpose of the Study:
- To identify novel substrates of the p35/cdk5 complex.
- To investigate the role of p35/cdk5 in regulating beta-catenin and presenilin-1 interactions.
- To establish a molecular framework connecting these proteins in AD.
Main Methods:
- Yeast two-hybrid screening to identify p35 binding partners.
- Glutathione S-transferase (GST) pull-down assays and co-immunoprecipitation to confirm protein interactions.
- Subcellular localization studies.
- In vitro kinase assays to demonstrate phosphorylation.
- Pharmacological inhibition of p35/cdk5 activity.
Main Results:
- Beta-catenin was identified as a novel binding partner of p35.
- p35/cdk5 directly phosphorylates beta-catenin.
- p35/cdk5 activity regulates the binding of beta-catenin to presenilin-1.
- Inhibition of p35/cdk5 reduced presenilin-1 binding to beta-catenin without altering protein levels.
Conclusions:
- p35/cdk5 binds and phosphorylates beta-catenin.
- p35/cdk5 modulates the interaction between beta-catenin and presenilin-1.
- These findings offer a novel molecular mechanism linking p35/cdk5, beta-catenin, and presenilin-1 in the context of Alzheimer's disease.
Related Concept Videos
Positive Regulator Molecules
Positive Regulator Molecules
Inhibition of Cdk Activity
Anaphase Promoting Complex
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the adherens...
Inhibition of CDK Activity

